JNJ Outshines ABBV in 2026 H2 with Conservative Balance Sheet

Johnson & Johnson (JNJ) has outshone AbbVie (ABBV) in the second half of 2026, according to a recent analysis. JNJ's premium valuation is justified by its conservative balance sheet and superior capital allocation flexibility.

JNJ trades at a 30% P/E premium to ABBV, with a price-to-earnings ratio (P/E) of 24.2x versus 18.8x for ABBV on a fiscal year one basis. When factoring in yield and growth, the premium is even more pronounced on a PEGY basis.

JNJ's lower payout ratio of 48% compared to ABBV's 62%, stronger buyback activity, lower leverage with a debt-to-equity ratio of 57% and debt-to-free cash flow of 6.88x, all contribute to its defensive profile.